FA is a very rare, genetic, recessive disease, affecting 1/50,000 people.
Originates from mutations in the “coding” of the mitochondria.
Discovered by Nicholaus Friedreich in the early 1860’s.
Both parents must have the dominant trait for a 25% chance of an offspring possessing the disease.
Not necessarily a disease that kills you, but eventually a wheelchair and regular assistance will be required.
Onset before age 20-25 year.
Amyotrophic lateral sclerosis (ALS), AKA "Lou Gehrig's Disease," is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed.
I have created this presentation for the CMTA, to be used to explain CMT at the high school level. It is also being used to explain CMT to family and friends. Enjoy!
FA is a very rare, genetic, recessive disease, affecting 1/50,000 people.
Originates from mutations in the “coding” of the mitochondria.
Discovered by Nicholaus Friedreich in the early 1860’s.
Both parents must have the dominant trait for a 25% chance of an offspring possessing the disease.
Not necessarily a disease that kills you, but eventually a wheelchair and regular assistance will be required.
Onset before age 20-25 year.
Amyotrophic lateral sclerosis (ALS), AKA "Lou Gehrig's Disease," is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed.
I have created this presentation for the CMTA, to be used to explain CMT at the high school level. It is also being used to explain CMT to family and friends. Enjoy!
Neuroradiology in multiple sclerosis
MRI in diagnosis of MS
MRI in D.D. of MS
MRI in monitoring disease progression and response to DMT
New imaging techniques
Disorders of amino acid metabolism
Disorders of renal amino acid transport
Disorders of carbohydrate metabolism and transport
Carbohydrate-deficient protein syndromes
carbohydrate metabolism and transport
Disorders of fatty acid oxidation
Disorders of purine and pyrimidine metabolism
Disorders of lipid and lipoprotein metabolism
Ceroid lipofuscinosis and other lipidoses.
Disorders of serum lipoproteins
Lysosomal disorders
Peroxisomal disorders
Disorders of metal metabolism
Porphyrias
Los días 11 y 12 de diciembre de 2014, la Fundación Ramón Areces celebró el Simposio Internacional 'Neuropatías periféricas hereditarias. Desde la biología a la terapéutica' en colaboración con CIBERER-ISCIII y el Centro de Investigación Príncipe Felipe. El tipo más común de estas patologías es la enfermedad de Charcot-Marie-Tooth, un trastorno neuromuscular hereditario con una prevalencia estimada de 17-40 afectados por 100.000 habitantes. Durante estos dos días, investigadores mostraron sus avances en la mejora del diagnóstico y el tratamiento y, por ende, de la aproximación clínica y la calidad de vida de las personas afectadas por estas patologías.
Reference-Harrison text book of internal medicine -20th edition
Slides by-Dr Jayasoorya P G,Junior resident,Department of General Medicine,Azeezia medical college,Kollam,Kerala
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic inflammatory neuropathy. CIDP is diagnosed according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria
https://www.youtube.com/watch?v=AYEhL1LdONY
Parkinsonism is a clinical syndrome and, typically, when the condition
appears to be idiopathic and responsive to levodopa therapy, is referred
to as Parkinson’s disease1
• The four cardinal features of the parkinsonian syndrome are:2
– Bradykinesia
– Muscular rigidity
– Resting tremor
– Postural instability (and gait impairment)
• These features are not always observed in every patient, at any given
time
To make a diagnosis of PD, the physician must distinguish between
different forms of parkinsonism:1
– Parkinson’s disease
– Secondary parkinsonism
– Parkinsonism as part of another neurodegenerative disorder (e.g., multiple
system atrophy, progressive supranuclear palsy, corticobasal degeneration, or
Lewy body dementia)
SCALES COMMONLY USED IN
PARKINSON’S DISEASE
RESEARCH
SCALES COMMONLY USED IN
PARKINSON’S DISEASE
RESEARCH
Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons). Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses. The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma). Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well. PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS). Currently, the best available therapy is reversal of the immune-deficient state, since there are no effective drugs that block virus infection without toxicity. Reversal may be achieved by using plasma exchange to accelerate the removal of the therapeutic agents that put patients at risk for PML. In the case of HIV-associated PML, immediately beginning anti-retroviral therapy will benefit most individuals. Several new drugs that laboratory tests found effective against infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication.
In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis but depends on the severity of the underlying disease and treatment received. Those who survive PML can be left with severe neurological disabilities.
Sequencing in management of Multiple sclerosisAmr Hassan
Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes.
A neuromuscular disorder that leads to weakness of skeletal muscles.
Symptoms
Causes
Prevention
Complications
Common tests & procedures
Neurological examination:
Repetitive nerve stimulation test:
Antibody test:
Pulmonary function tests (PFTs): To check any breathing difficulty.
CT scan: To rule out a presence of tumor in thymus.
Magnetic resonance imaging (MRI): MRI of the chest is performed to rule out a presence of tumor in thymus.
Edrophonium (Tensilon) test:
Medication
Procedures
Nutrition
Prediction of outcome of Multiple sclerosisAmr Hassan
Prediction of outcome of Multiple sclerosis
An understanding of the natural history of multiple sclerosis(MS) in a patient is important to begin proper treatment at the correct time, especially when there is a high risk for poor prognosis. Factors that predict unfavorable prognosis are a primary or secondary progressive course, older age at disease onset, short interval between first and second attacks, initial cerebellar or pyramidal symptoms, a large number of functional systems involved at onset, moderate to severe disability within the first 2 years, and the presence of typical plaques or greater lesion volume shown by magnetic resonance imaging results during the first 5 years. However, there are no established laboratory tests able to predict long-term prognosis.
Lifestyle modification in epilepsy
Lifestyle Modifications
Lifestyle modifications can include:
Adequate sleep: Fatigue is one of the most common seizure triggers, and disrupted sleep can make the brain more vulnerable to misfiring.
Avoiding drugs and alcohol: These can be triggers for seizures in patients with epilepsy. Even one or two drinks can provoke seizures.
Minimizing emotional stress: Although there is not definitive proof that stress causes seizures, those who maintain healthy stress levels have reported that they believe it reduces their risk.
Frequency of exercise: In addition to a range of health benefits, regular exercise can help reduce risk of seizure. However, you should consult your physician before starting a new exercise routine, as some exercise can, rarely, cause seizures.
Childhood demyelinating syndromes
In the past decade, the number of studies related to demyelinating diseases in children has exponentially increased. Demyelinating disease in children may be monophasic or chronic. Typical monophasic disorders in children are acute disseminated encephalomyelitis and clinically isolated syndromes, including optic neuritis and transverse myelitis. However, some cases of acute disseminated encephalomyelitis or clinically isolated syndrome progress to become chronic disorders, including multiple sclerosis and neuromyelitis optica. This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management.
Diabetic polyneuropathy
Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.
Excessive daytime sleepiness
The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications. Other potential causes of excessive daytime sleepiness include certain medical and psychiatric conditions and sleep disorders, such as narcolepsy.
Vagal Nerve stimulation
Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath. Serious side effects may include trouble talking and cardiac arrest.
Dystonia
Dystonia is a movement disorder in which your muscles contract involuntarily, causing repetitive or twisting movements.
The condition can affect one part of your body (focal dystonia), two or more adjacent parts (segmental dystonia) or all parts of your body (general dystonia). The muscle spasms can range from mild to severe. They may be painful, and they can interfere with your performance of day-to-day tasks.
Dystonia: Causes, Types, Symptoms, and Treatments
Trigeminal neuralgia is sudden, severe facial pain. It's often described as a sharp shooting pain or like having an electric shock in the jaw, teeth or gums.
Trigeminal neuralgia
Contents
Overview
Symptoms
Causes
Diagnosis
Treatment
Nootropics and smart drugs are natural or synthetic substances that can be taken to improve mental performance in healthy people.
They have gained popularity in today’s highly competitive society and are most often used to boost memory, focus, creativity, intelligence and motivation.
Here’s a look at the ]best nootropics and how they enhance performance.
Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents
1 Causes
1.1 Early-onset nystagmus
1.2 Acquired nystagmus
1.3 Other causes
2 Diagnosis
2.1 Pathologic nystagmus
2.2 Physiological nystagmus
3 Treatment
4 Epidemiology
Basics of Neuroradiology
Neuroradiology is an essential tool in management of patients with neurological and neurosurgical disorders. The aim of this presentation will be to acquaint the reader to understand how images are formed on a computed tomography (CT) and magnetic resonance imaging (MRI) along with a review of the relevant neuroanatomy. This understanding will be helpful to the reader in interpretation of images and diagnosis of various neurological disorders.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
2. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
3. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
4. 1) Hereditary Motor & Sensory Neuropathies
=CMT
CMT Type 1
CMT Type 2
CMT Type 3
CMT Type 4
CMT Type 5
CMT Type 6
CMT Type 7
XL CMT
5. 1) Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy (CMT)
Type1:
Subtypes
Disorder
Pattern of
inheritance
Protein Location
CMT 1A AD PMP-22 17p11
CMT 1B AD P0 1q22
CMT 1C AD LITAF 16p13
CMT 1D AD EGR2 10q21
CMT 1E
AD
P0 protein;
1q22
CMT 1F
AD Neurofilament light
chain
8p21
6. 1) Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy (CMT)
Type 1:
Clinical Picture
(CMT) Type 1A:
1st or 2nd decade.
Symmetrical distal LL weakness (intrinsic foot, peroneal & ant tibial
muscles) Champaign bottle shape
UL involvement in 2/3 of cases.
↓ Reflexes
Hypertrophic nerves
± UL Tremors = (Rousy lévy syndrome)
Retain ambulance for life
7. 1) Hereditary Motor & Sensory Neuropathies
(CMT) Type 1B, 1C, 1D,1E & 1F:
Clinically similar to 1A with varying severity
Electrophysiology: Demyelinating
↓ NCV ( Cut off between CMT 1 & 2 38 m/sec)
Biopsy: Onion bulb appearance
8. 1)Hereditary Motor & SensoryNeuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type 2 :
Subtypes
Disorder Pattern of inheritance Gene Location
CMT 2A AD KIF1Bβ 1p36
CMT 2B AD RAB7 3q13
CMT 2C AD 12q23-q24
CMT 2D AD GARS 7p15
CMT 2E AD NF-68 8p21
CMT 2F AD HSPB1 (HSP 27) 7q11
CMT 2G AD 12q12
CMT 2L AD HSPB8 12q24
AR-CMT2A AR Lamin A/C 1q21
AR-CMT2B AR 19q13
Andermann AR KCC3 15q13
9. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type 2 :
Clinical picture
Disorder Clinical picture
CMT 2A
Onset of neuropathy by 10yr of age;
progresses to distal weakness and atrophy
in legs; mild sensory disturbance
CMT 2B
Onset 2nd- 3rd decade; severe sensory
loss with distal ulcerations.
CMT 2C
Vocal cord and diaphragmatic
weakness
10. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
2 :
Clinical picture
CMT 2D
Arm>leg weakness; onset in 2nd-3rd
decade.
CMT 2E
Variable onset and severity; ranging from
DSS-like to CMT-2 phenotype
CMT 2F Severe distal weakness & Fasciculations
CMT 2G Proximal >distal weakness
CMT 2L Onset 15 to 33 years , Distal weakness
11. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
2 :
Clinical picture
AR-CMT2A
Onset of neuropathy in 2nd decade;
progresses to severe distal weakness and
atrophy
AR-CMT2B 3rd & 4th decade,Distal weakness
Andermann 1st decade,Hypotonia
12. 1) Hereditary Motor & Sensory Neuropathies
b- Hereditary Motor & Sensory Neuropathy (CMT)
Type 2:
Electrophysiology: Axonal
SNAP: ↓ Amplitude or even absent
Biopsy: Preferential loss of large myelinated fibers without
significant demyelination, there may be clusters of of regenerating
myelinated fibers
13. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
3 :
Subtypes & Clinical picture
Disorder Locus;Gene Clinical picture
DSS=Dejerene-
Sottas
syndrome
PMP22,MPZ,GJB
DGR2,NEFL
(dominant)
PRX. MTMR2
(recessive)
Onset before 3yr age
with delayed motor
development, severe
Weakness, atrophy,
and sensory loss
Congenital
Hypomyelinating
Neuropathy
(CHN)
PMP22, MPZ
(dominant); EGR2
(recessive)
Hypotonic at birth,
developing into
clinical picture often
similar to DSS
14. 1) Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy (CMT)
Type 3 :
Electrophysiology: Demyelinating
↓ NCV < 10 m/sec
Biopsy: Prominent Onion bulb appearance
15. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
4 :
Subtypes
Disorder Pattern of
inheritance
Gene; Location
CMT-4A AR GDAPI 8q13-q21;
CMT-4B1 AR MTMR2 11q22;
CMT-4B2 AR SBF2 11p15;
CMT-4C AR KIAA1985 5q23-33;
CMT-4D AR NDRG1 8q24;
16. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
4 :
Disorder Pattern of
inheritance
Gene; Location
CMT 4E AR EGR2 10q21
CMT 4F AR Periaxin 19q13
HMSN-Russe
(4G)
AR 10q23
CMT 4H AR FGD4 12q12
CMT 4J AR FIG4 6q21
17. 1)Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy(CMT)Type
4 :
Subtypes
Disorder Clinical Picture
CMT-4A Early-childhood onset, progression to wheelchair
dependency; both demyelinating and axonal phenotypes
CMT-4B1 Early-childhood onset, may progress to wheelchair
dependency; focally folded myelin sheaths
CMT-4B2 Childhood onset; progressive; focally folded myelin
sheaths; glaucoma
CMT-4C Infantile to childhood onset; progressing to wheelchair
dependency
CMT-4D Childhood onset; severe disability by 50yr; hearing loss,
dysmorphic features
18. 1) Hereditary Motor & Sensory Neuropathies
Hereditary Motor & Sensory Neuropathy (CMT) Type 4 :
Electrophysiology: Demyelinating
↓ NCV 20-30 m/sec
Biopsy:
focally folded myelin sheaths (tomacula) in type CMT-4B1
CMT-4B2
Segmental demyelination
Onion bulb appearance
Myelinated axon loss: Large > Small
19. 1) Hereditary Motor & Sensory Neuropathies
XL Hereditary motor & sensory neuropathy (CMT)
Xq13.1; CJB1 (Connexin 32)
Clinically:
Phenotypically similar to CMT 1
Males are more severely affected
Affected females -- mild or asymptomatic
Transient ataxia ,dysarthria
CNS white matter abnormalities on MRI studies
Electrophysiology:
↓ NCV in males
↓ NCV & amplitudes in females
Abnormal BAEP
22. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
23. 2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
Genetics
AD , 17P11.2 ,PMP 22
Clinically:
2nd or 3rd decade
↑ susceptibilityof PN to mechanical traction ,compression or minor trauma
Recurrent sudden painless episodes of isolated mononueropathy commonly
affecting
Common peroneal, brachial plexus,radial& median nerves
Complete recovery in days or weeks
Less common presentations
-Progressive monoeuropathy
-Chronic sensory polyneuropathy
-Chronic sensory motor neuropathy
-Transient positional sensory symptoms
24. 2- Hereditary Neuropathy with liability to
Pressure Palsy (HNPP)
Electrophysiology:
Prolonged distal motor latencies with focal slowing of
ulnar & fibular nerve at the compression sites
Diffuse reduction of sensory nerve action potential
amplitudes
Biopsy:
Focal sausage-like thickening of myelin termed Tomacula
due to redundant myelin loop as a result of overgrowth
of myelin spiral
25. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
26. 3- Hereditary Sensory & Autonomic
Neuropathies (HSAN)
Subtypes
Disorder
Pattern of
inheritance Gene Location
I AD SPTLC1 9q22
II AR HSN2 12p13
III AR IKBKAP 9q31
IV
AR TRKA/ NGF
receptor
1q21
V AR
27. 3- Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN) type I
Clinically:
2nd 4th decade
Superficial & deep sensory loss affecting feet & legs acrodystrophic neuropathy=
Acromutilation
Lancinating or shooting pain
± Distal muscle weakness ( D.D. CMT type 2B)
Electrophysiology: Axonal
SNAP Amplitude ↓
Motor CV NL but CMAP Amplitude may ↓ in late stages
Biopsy: Sural N biopsy : Severe loss of unmyelinted & small myelinated axons and to lesser
degree loss of large myelinated fibers.
28. 3- Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN) type II
Clinically:
Started in infancy
Panmodal sensory affection -> Acromutilation
Dysautonomia
Variable features : spastic para , retinitis pigmentosa ,motor weakness or keratitis
Electrophysiology: Axonal
SNAP Amplitude ↓
Biopsy: Sural N biopsy : loss of large & small axons
29. 3- Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN) type III
=Familial Dysautonomia = Riley Day Syndrome
Clinically:
Childern of Ashkenazi Jewish ethnicity
Autonomic > sensory
Begin at birth ( poor feeding, esophageal dysmotility ,vomiting ,recuurent
fever & chest infection)
Emotional stimuli provoke episodic hypertension, profuse sweating
&marked skin blotching due to defective autonomic control
Defective lacrimation ,absence of tongue papillae
Hypotonia delayed motor milestones, gait ataxia, stunted growth &
scoliosis
Potentially life threatening condition due to aspiration pneuomonia,
autonomic crises
30. 3- Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN)
type III =Familial Dysautonomia = Riley Day
Syndrome
Electrophysiology: Axonal
SNAP Amplitude ↓
Biopsy:
Sural N biopsy : loss of small & large axons
31. Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN) type IV
Clinically:
Congenital insensitivity to pain
Anhidrosis
Recurrent fever
Self mutilating behaviour
Mild MR
Loss of C axons
Electrophysiology:
SNAP are preserved
Biopsy: Sural N biopsy : loss of myelinted & unmyelinated axons
32. Hereditary Sensory & Autonomic Neuropathies
(HSAN)
Hereditary Sensory & Autonomic Neuropathies (HSAN) typeV
Clinically:
Congenital, or Early childhood
Absence of pain
No anhidrosis
Loss of Aδ-axons
Electrophysiology:
SNAP are preserved
Biopsy: Sural N biopsy : SELECTIVE loss of small myelinted
fibers
33. Other Hereditary Sensory Neuropathies
Disorder gene locus inheritance onset clinical
Absent pain NGF-b 1p13 Recessive
Early childhood
to Adult
Absence of
pain
No anhidrosis
Inability to
experience pain
SCN
9A
2q24 Recessive Congenital
Absence of
pain
No anhidrosis
Erythromelalgia
SCN
9A
2q24 Dominant Childhood
Pain, distal
Episodic
Biemond ataxia Dominant 19 to 30 years Sensory loss
Ulcero-mutilation Dominant 5 to 30 years Acromutilation
Spastic
paraparesis
5p15 Recessive 1 to 5 years Acromutilation
35. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
36. 4- Distal Hereditary Motor Neuropathies
(HMN)= Distal Spinal Muscular Atropthy (SMA).
Subtypes &Clinical picture:
Disorder Gene/Locus Clinical picture
HMN-5 7p; GARS
Arm> leg weakness; onset in 2nd- 3rd
decade; no sensory involvement
HMN 7 2q14 Vocal cord involvement
HMARD 11q13;
Distal infantile SMA with diaphragm
paralysis
HMNJ 9p21; 1-p12 Childhood-onset distal weakness (Jerash type)
HMN
2p13;
DCTNl
Progressive hand >leg weakness and atrophy,
vocal fold paralysis & facial weakness
37. HEREDITARY NEUROPATHIES
A) Non Syndromic Hereditary Neuropathies:
1- Hereditary Motor & Sensory Neuropathies (CMT).
2- Hereditary Neuropathy with liability to Pressure
Palsy (HNPP)
3-Hereditary Sensory & Autonomic Neuropathies
(HSAN).
4- Distal Hereditary Motor Neuropathies (HMN).
B) Syndromic Hereditary Neuropathies:
38. B) Syndromic Hereditary Neuropathies
1) Demyelinating Dominant
Disorder Gene / Locus Associated
features
Wardeenburg
type IV
22q13;
SOX10
CNS & PNS
dysmyelination
Hirschsprung
disease
49. Diagnosis Of Hereditary Neuropathies
History taking (hereditary cause is suggested)
Examination
Lab work to exclude causes of acquired neuropathies
Neurophysiological study
Biopsy
Genetic study
63. Clinical Case
40ys old female patient presenting with gradual progressive
weakness both UL & LL, D>P, UL>LL associated with distal
wasting
NC study showed axonal motor affection with no sensory
affection
keywords
UL involvement
Pure motor
Axonal